Navigation Links
ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
Date:6/13/2008

ix months of therapy," said Graeme Jones, M.D., lead investigator of the AMBITION trial and Associate Professor at the University of Tasmania in Hobart, Australia. "Overall, these compelling results further establish the efficacy and safety of ACTEMRA in treating the chronic signs and symptoms of RA that dramatically affect the lives of patients."

About AMBITION Study

The main AMBITION (Actemra versus Methotrexate double-Blind Investigative Trial In mONotherapy) study, a two-arm, randomized, double-blind, placebo-controlled study, was designed to evaluate the non-inferiority and subsequent superiority of ACTEMRA monotherapy in patients with RA compared with methotrexate alone at 24 weeks. Patients who had not received methotrexate for at least six months beforehand were randomized to receive either ACTEMRA (8 mg/kg) intravenously every four weeks plus placebo capsules weekly or placebo infusions every four weeks plus methotrexate weekly. The study evaluated 673 patients from 252 trial sites in 18 countries, including the United States.

In the AMBITION study, 70 percent, 44 percent and 28 percent of patients in the ACTEMRA (8 mg/kg) arm achieved ACR20, ACR50 and ACR70 compared, respectively, with 53 percent, 34 percent and 15 percent, respectively, of patients treated with methotrexate alone. Disease remission (DAS28 <2.6) was demonstrated in 34 percent of ACTEMRA patients compared with 12 percent of patients in the control group. A higher proportion of ACTEMRA (8 mg/kg) patients achieved a significant EULAR response(3) as early as the second week in the trial.

ACTEMRA was generally well tolerated; the most common adverse reactions reported more frequently in the ACTEMRA arm of the AMBITION trial were upper respiratory tract infections, headache and nasopharyngitis.

About RADIATE Study

The RADIATE (RheumAtoiD ArthritIs Study in Anti-TNF FailurEs) trial, a three-arm, randomized, double-blind, placebo-controlled study, was desi
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
2. New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients
3. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
4. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
5. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
6. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
7. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
8. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
9. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
10. Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
11. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Most osteoporosis patients want a choice in the ... sponsored by Mission Pharmacal Company. The survey, conducted by ... support community, revealed that 74 percent of osteoporosis patients ... form other than a pill or a tablet. ...
(Date:1/15/2014)... LAWRENCEVILLE, N.J. , Jan. 15, 2014  Celsion Corporation (the ... it has received commitments from institutional investors to purchase ... common stock in an at-the-market registered direct offering, led ... Company entered into definitive purchase agreements with these investors ...
(Date:1/15/2014)... Jan. 15, 2014  Manufacturers, suppliers and distributors of ... to protect their most important business assets, intellectual ... ) Because of the highly-competitive nature ... one of the most litigious industry sectors of ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... Feb. 24, 2011 GlaxoSmithKline (GSK), one of ... 2010 Environmental Stewardship Award from Nalco Company (NYSE: ... ongoing efforts to reduce its climate change impact ... http://photos.prnewswire.com/prnh/20101231/NALCOLOGO ) The Environmental Stewardship ...
... N.C., Feb. 24, 2011 Chimerix, Inc., a pharmaceutical ... announced today that Kenneth I. Moch, President and Chief ... Health Care Conference on March 1, 2011 at 3:00 ... New York City, NY. Mr. Moch will ...
Cached Medicine Technology:GlaxoSmithKline Wins Environmental Stewardship Award 2GlaxoSmithKline Wins Environmental Stewardship Award 3Chimerix to Present at the Citi 2011 Global Health Care Conference 2Chimerix to Present at the Citi 2011 Global Health Care Conference 3
(Date:4/17/2014)... By discovering a new mechanism that allows blood to ... UC Irvine and the Salk Institute have opened the ... stroke-induced brain damage. , A complex and devastating neurological ... primary reason for disability in the U.S. The blood-brain ... blood-borne material into the brain, causing the permanent deficits ...
(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit ... issues, published a comprehensive review today examining the current ... virus. The review calls for improved global surveillance strategies ... the recent outbreak of Ebola in West Africa that ... countries of Guinea and Liberia. According to the ...
(Date:4/17/2014)... off depression among retirees, particularly among those who live ... The Journals of Gerontology, Series B: Psychological Sciences and ... Use and Depression Among Retired Older Adults in the ... that Internet use reduced the probability of a depressed ... , Late-life depression affects between 5 and 10 million ...
(Date:4/17/2014)... NEW YORK (17 April 2014) Population Council scientists and ... is safe, stable, and can prevent the transmission of ... and rectum in animals: HIV, herpes simplex virus 2 ... provides the first data that the gel is effective ... of efficacy in the vagina against all three viruses ...
(Date:4/17/2014)... April 17, 2014 Meaningful long-term survival ... cancer of the abdomen when treated with cytoreductive ... to a first-of-its-size analysis by physicians at Wake ... has the largest reported, single-center experience with cytoreductive ... Levine, M.D., and analysis of 20 years, worth ...
Breaking Medicine News(10 mins):Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Internet use may cut retirees' depression 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2
... Calif., Oct. 10 AlphaDetail, Inc., a leader,in primary ... Life Sciences Industry, continues to affirm its commitment to ... on the east coast. AlphaDetail will open a ... This will benefit a large number of clients located ...
... Oct. 10 The Pennsylvania,Department of Health today ... (CDC) advisory for consumers not to eat Banquet ... due to possible,Salmonella contamination., "Federal officials have ... want to ensure Pennsylvanians are taking the,appropriate measures ...
... Inc. (OTC,Bulletin Board: SCIE) announced today that it ... Company,s quality system from the Notified,Body G-MED. SpectraScience ... II.3 of the European directive 93/42/EEC. In addition, ... Jim Hitchin the Company,s CEO said, "This certification ...
... 10 Good Shepherd,Rehabilitation Network has expanded ... The virtual store at, http://www.rehabilitystores.com with ... of secure online shopping specifically for those ... and their caregivers., "Rehability offers a ...
... Rural/Metro,Corporation announced that a majority of its ... Capital Management LLC, the Company,s,largest stockholder. During the ... and constructive dialogue. The Board,s desire is to ... remains committed,to doing what is best to enhance ...
... likely to develop breathing problems, study finds, , , WEDNESDAY, Oct. ... in their first month of life were more likely to ... a new study found. , Danish researchers found that infants ... influenzae or Moraxella catarrhalis bacteria had more ...
Cached Medicine News:Health News:AlphaDetail, Inc. Affirms Commitment to Local East Coast Presence 2Health News:Salmonella Outbreak Traced to Banquet and Store Brand Frozen Pot Pies 2Health News:SpectraScience Receives Final European Certification 2Health News:Those With Disabilities as Well as Aging Population Throughout Country Now Have Access to Thousands of Specialized Products 2Health News:Rural/Metro Board of Directors Meets With Accipiter Capital Management 2Health News:Rural/Metro Board of Directors Meets With Accipiter Capital Management 3Health News:Early Bacterial Infection May Boost Asthma Risk 2Health News:Early Bacterial Infection May Boost Asthma Risk 3
... Affinity pacemaker family offers ... truly automatic devices. Featuring ... of advanced technologies ever ... pacemaker incorporates the exclusive ...
Medtronic, Inc., a world leader in therapies for restoring people with chronic conditions to full life, introduces the AT500 Pacing System for the management of atrial tachyarrhythmias and bradycardi...
The Guidant INSIGNIA Ultra pacing system offers sophisticated patient-specific, easy-to-use features for simplified patient management and enhanced patient safety....
... Powerful, flexible, and fast, the ... combines leading edge technologies with user-oriented ... The integrated SONO MR package consists ... and control, including HI COMPOUND multi-angle ...
Medicine Products: